Open Payments Data Analysis of General and Fellowship-trained Surgeons Receiving Industry General Payments From 2016 to 2020: Payment Disparities and COVID-19 Pandemic Impact
- PMID: 37314222
- DOI: 10.1097/SLA.0000000000005951
Open Payments Data Analysis of General and Fellowship-trained Surgeons Receiving Industry General Payments From 2016 to 2020: Payment Disparities and COVID-19 Pandemic Impact
Abstract
Objective: To characterize industry nonresearch payments made to general and fellowship-trained surgeons between 2016 and 2020.
Background: The Centers for Medicare & Medicaid Services Open Payments Data (OPD) reports industry payments made to physicians related to drugs and medical devices. General payments are those not associated with research.
Methods: OPD data were queried for general and fellowship-trained surgeons who received general payments from 2016 to 2020. Payments' nature, amount, company, covered product, and location were collected. Surgeons' demographics, subspecialty, and leadership roles in hospitals, societies, and editorial boards were evaluated.
Results: From 2016 to 2020, 44,700 general and fellowship-trained surgeons were paid $535,425,543 in 1,440,850 general payments. The median payment was $29.18. The most frequent payments were for food and beverage (76.6%) and travel and lodging (15.6%); however, the highest dollar payments were for consulting fees ($93,128,401; 17.4%), education ($88,404,531; 16.5%), royalty or license ($87,471,238; 16.3%), and travel and lodging ($66,333,149; 12.4%). Five companies made half of all payments ($265,654,522; 49.6%): Intuitive Surgical ($128,517,411; 24%), Boston Scientific ($48,094,570; 9%), Edwards Lifesciences ($41,835,544, 7.8%), Medtronic Vascular ($33,607,136; 6.3%), and W. L. Gore & Associates ($16,626,371; 3.1%). Medical devices comprised 74.7% of payments ($399,897,217), followed by drugs and biologicals ($33,945,300; 6.3%). Texas, California, Florida, New York, and Pennsylvania received the most payments; however, the top dollar payments were in California ($65,702,579; 12.3%), Michigan ($52,990,904, 9.9%), Texas ($39,362,131; 7.4%), Maryland ($37,611,959; 7%), and Florida ($33,417,093, 6.2%). General surgery received the highest total payments ($245,031,174; 45.8%), followed by thoracic surgery ($167,806,514; 31.3%) and vascular surgery ($60,781,266; 11.4%). A total of 10,361 surgeons were paid >$5000, of which 1614 were women (15.6%); in this group, men received higher payments than women (means, $53,446 vs $22,571; P <0.001) and thoracic surgeons received highest payments (mean, $76,381; NS, P =0.14). A total of 120 surgeons were paid >$500,000 ($203,011,672; 38%)-5 non-Hispanic White (NHW) women (4.2%) and 82 NHW (68.3%), 24 Asian (20%), 7 Hispanic (5.8%), and 2 Black (1.7%) men; in this group, men received higher payments than women (means, $1,735,570 vs $684,224), and NHW men received payments double those of other men (means, $2,049,554 vs $955,368; NS, P =0.087). Among these 120 highly paid surgeons (>$500,000), 55 held hospital and departmental leadership roles, 30 were leaders in surgical societies, 27 authored clinical guidelines, and 16 served on journal editorial boards. During COVID-19, 2020 experienced half the number of payments than the preceding 3 years.
Conclusions: General and fellowship-trained surgeons received substantial industry nonresearch payments. The highest-paid recipients were men. Further work is warranted in assessing how race, gender, and leadership roles influence the nature of industry payments and surgical practice. A significant decline in payments was observed early during the COVID-19 pandemic.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
J.A.S.-B. (Open Payments link: https://openpaymentsdata.cms.gov/physician/1543183 ) reports food and beverage payments from Lifecell Corporation, Novartis, Astellas Pharma, Mallinckridt, KCI USA, Acell Inc., Davol Inc., Allergan Inc., E.R. Squibb & Sons, Sientra, and Axogen; and education payments from W.L. Gore & Associates and Axogen Inc. J.M.V.M. (Open Payments link: https://openpaymentsdata.cms.gov/physician/105954 ) reports food and beverage payments from Olympus American Inc., W.L. Gore & Associates Inc., Lifecell Corporation, Merck Sharp & Dohme, Davol Inc., Genentech USA, Allergan Inc., Intuitive Surgical Inc., Amgen Inc., and Bard Peripheral Vascular. Reports being part of advisory boards for Castle Biosciences and United Healthcare. Reports owning stocks of Doximity. The remaining authors report no conflicts of interest.
References
-
- McCartney M, Bergeron Hartman R, Feldman H, et al. How are declarations of interest working? A cross-sectional study in declarations of interest in healthcare practice in Scotland and England in 2020/2021. BMJ Open. 2022;12:e065365.
-
- Krimsky S, Rothenberg LS. Financial interest and its disclosure in scientific publications. JAMA. 1998;280:225–226.
-
- Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373–380.
-
- Field MJ, Lo B Conflict of interest in medical research, education, and practice; 2009.
-
- Sah S, Fagerlin A, Ubel P. Effect of physician disclosure of specialty bias on patient trust and treatment choice. Proc Natl Acad Sci USA. 2016;113:7465–7469.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous